Harrow, Inc. 2026 Q1 - Results - Earnings Call Presentation (NASDAQ:HROW)
Harrow, Inc. published its Q1 2026 earnings call presentation on May 19, 2026. The article features the slide deck released by Harrow, Inc. in conjunction with their earnings call, prepared by Seeking Alpha's transcripts team. It provides key details for investors and followers of HROW.
Insider Buying: Adrienne Graves Acquires Shares of Harrow Inc (HROW)
Adrienne Graves, a Director at Harrow Inc, purchased 1,000 shares of the company on May 18, 2026, increasing her total ownership to 1,000 shares. Harrow Inc (HROW) is engaged in the development, production, and sale of innovative pharmaceutical products. The stock was trading at $31.07 on the day of the purchase, and its GF Value suggests it is modestly undervalued at $40.59.
Harrow: Demand Keeps It Interesting, Valuation Keeps It A Hold
Harrow is currently rated as a Hold despite strong demand for its ophthalmic products, due to execution risks revealed in Q1 2026. The company missed revenue and adjusted EBITDA expectations, highlighting challenges in converting prescription growth into predictable financial results, particularly with products like VEVYE and IHEEZO. Achieving its 2026 guidance will require significant revenue acceleration and EBITDA recovery, but the market's current valuation already appears to factor in a successful turnaround.
Harrow, Inc. 2026 Q1 - Results - Earnings Call Presentation
This article provides the slide deck presented by Harrow, Inc. during their Q1 2026 earnings call on May 19, 2026. The slide deck contains crucial information discussed by the company regarding their financial performance and outlook. This publication offers investors and interested parties direct access to the materials used in the presentation.
Harrow director Adrienne Graves buys $31,070 in company stock By Investing.com
Adrienne L. Graves, a director at HARROW, INC. (NASDAQ: HROW), recently purchased 1,000 shares of the company's common stock for a total of $31,070. This acquisition comes as the stock trades near $30.90, down 37% year-to-date, with InvestingPro analysis suggesting the company may be undervalued. This insider purchase follows a recent financial report where Harrow Health Inc. missed Q1 2026 earnings and revenue expectations.
Insider Buying: Adrienne Graves Acquires Shares of Harrow Inc (HROW)
Adrienne Graves, a Director at Harrow Inc (HROW), recently purchased 1,000 shares of the company, increasing her total ownership to 1,000 shares. The transaction occurred on May 18, 2026, with shares trading at $31.07. According to GuruFocus's GF Value of $40.59, Harrow Inc is considered modestly undervalued with a price-to-GF-Value ratio of 0.77.
Harrow director Lauren Silvernail buys $31,000 in company stock
Harrow director Lauren P. Silvernail purchased 1,000 shares of HARROW, INC. common stock for $31,000 on May 18, 2026, increasing her direct holdings to 1,000 shares. This insider buying occurs as the stock is down 37% year-to-date and follows a recent Q1 2026 earnings report where Harrow Health Inc. missed revenue and EPS expectations.
Harrow director Adrienne Graves buys $31,070 in company stock
Harrow director Adrienne Graves recently purchased 1,000 shares of HARROW, INC. (NASDAQ: HROW) common stock for $31.07 per share, totaling $31,070. This acquisition occurred while the stock was trading near $30.90, down 37% year-to-date and considered undervalued. The purchase follows Harrow Health Inc.'s disappointing Q1 2026 financial results, which missed EPS and revenue expectations.
Harrow (HROW) director purchases 1,000 common shares at $31.00 price
Harrow, Inc. director Lauren P. Silvernail purchased 1,000 shares of Harrow common stock in an open-market transaction at $31.00 per share. This transaction marks an initial reported stake, bringing Silvernail's direct ownership to 1,000 common shares. The Form 4 filing indicates a neutral impact and positive sentiment regarding this insider trade.
Harrow (HROW) director Adrienne Graves buys 1,000 shares at $31.07
Harrow, Inc. director Adrienne L. Graves purchased 1,000 shares of common stock at $31.07 per share in an open-market transaction on May 18, 2026. This acquisition brings her direct holdings to 1,000 shares, establishing a new personal equity position in the company. The Form 4 filing indicates a positive sentiment towards the company from an insider perspective.
[Form 4] HARROW, INC. Insider Trading Activity
Harrow, Inc.'s Chief Scientific Officer, Amir Shojaei, reported the acquisition of 10,000 restricted stock units (RSUs) through a Form 4 filing. These RSUs, which represent a contingent right to one share of common stock each, vest in full on May 15, 2029, provided Shojaei continues his service to the company. This transaction is classified as compensation rather than an open-market trade.
Harrow’s TRIESENCE Phase 3 Milestone Adds New Dimension To Growth Story
Harrow has received FDA clearance for its Investigational New Drug application for TRIESENCE, allowing a Phase 3 clinical trial for ocular inflammation and pain after cataract surgery to proceed. This milestone provides a new clinical catalyst for the company, diversifying its growth story beyond earnings guidance. While the trial adds to R&D costs and potential losses, a successful outcome could open up a significant market and reduce reliance on its current product portfolio, such as VEVYE and IHEEZO.
Harrow, Inc. CEO Mark L. Baum buys $302,000 in common stock
Harrow, Inc. CEO Mark L. Baum purchased 10,000 shares of the company's common stock for $302,000 following a 19% stock decline, signaling confidence despite recent missed financial forecasts. The company's Q1 2026 results fell short of expectations, leading Cantor Fitzgerald to adjust its price target downwards. InvestingPro suggests the stock remains undervalued, offering additional insights for investors.
Harrow (HROW) CEO Mark Baum acquires 10,000 shares in open-market buy
Harrow, Inc.'s CEO, Mark L. Baum, purchased 10,000 shares of the company's common stock in an open-market transaction. The shares were acquired at a weighted average price of $30.20, with individual trades ranging from $30.18 to $30.34. Following this acquisition, Baum directly owns 2,996,130 shares of Harrow common stock.
Harrow (NASDAQ: HROW) CFO adds 3,500 shares in open-market buy
Harrow, Inc.'s President and CFO, Andrew R. Boll, purchased 3,500 shares of company common stock in two open-market transactions on May 14, 2026, at $29.90 per share. Following these acquisitions, Boll directly owns 814,679 Harrow common shares. This insider buy signals a positive sentiment and increased direct ownership by a key executive.
Harrow Inc (HROW) Shares Surge 3.5% -- What GF Score of 82 Tells Investors
Harrow Inc (HROW) shares surged 3.5% today, but insider selling and a high forward P/E ratio suggest caution despite the stock being identified as "Modestly Undervalued" by GF Value™. The company boasts a strong GF Score™ of 82/100, driven by significant growth potential (9/10), yet its financial strength is weak (4/10). Investors are advised to weigh the undervaluation and growth prospects against the insider selling and unfavorable P/E.
Why Harrow (HROW) Is Down 25.9% After Q1 Miss And Reaffirmed 2026 Guidance – And What's Next
Harrow, Inc. (HROW) experienced a significant stock drop after missing Q1 2026 revenue and earnings expectations, primarily due to an $8 million non-recurring VEVYE adjustment. Despite this, management reaffirmed its full-year 2026 revenue guidance of $350 million to $365 million, indicating confidence in accelerated demand for its ophthalmic products. The article suggests that while the Q1 miss highlights risks related to product dependence and reimbursement, the reaffirmed guidance will be key to the company's investment narrative moving forward.
Transcript: Harrow Q1 2026 Earnings Conference Call
Harrow Inc. reported Q1 2026 revenues of $44.2 million and an adjusted EBITDA of negative $12.7 million, with revenue impacted by an $8 million gross-to-net adjustment related to their Vivi product. Despite this, the company reaffirmed its full-year 2026 revenue guidance of $350 million to $365 million, driven by strong demand across core products like Vivi, IHESO, and Triessense, and the recent expansion of its sales force. Harrow anticipates significant growth in the second half of 2026 due to improved pricing strategies, new product launches, and clinical milestones.
HROW: Strong demand and commercial expansion support reaffirmed 2026 revenue guidance of $350M–$365M
Despite a one-time adjustment impacting Q1 2026 revenue for Harrow, Inc. (HROW), the company reaffirmed its 2026 revenue guidance of $350M–$365M. This affirmation is based on strong demand for key products and the completion of commercial expansion efforts. Accelerated growth is anticipated in the second half of 2026.
Earnings Flash (HROW) Harrow, Inc. Reports Q1 Revenue $44.2M, Vs. FactSet Est of $52.4M
Harrow, Inc. (HROW) announced its Q1 revenue was $44.2 million, which fell short of the FactSet estimate of $52.4 million. This earnings flash provides a snapshot of the company's financial performance for the quarter.
Harrow Announces First Quarter 2026 Financial Results
Harrow, Inc. announced its financial results for the first quarter ended March 31, 2026, highlighting record performance for VEVYE® despite a non-recurring revenue adjustment of $8 million. The company reaffirmed its full-year 2026 revenue guidance of $350 million to $365 million, driven by strong demand for key products like VEVYE, IHEEZO®, and TRIESENCE®. Revenues for the quarter were $44.2 million, with a net loss of $27.6 million, and cash and cash equivalents stood at $94.6 million.
Harrow Health falls on revenue miss despite strong product demand
Harrow Health (NASDAQ:HROW) reported first-quarter results that missed analyst expectations, causing its shares to fall 7.8% in after-hours trading. The company attributed the revenue miss to a non-recurring adjustment related to VEVYE coverage, emphasizing strong underlying demand for its products like VEVYE, IHEEZO, and TRIESENCE. Despite the quarterly financial miss, Harrow reaffirmed its full-year 2026 revenue guidance, citing strong prescription performance and demand across its portfolio.
Opaleye entities report 7.61% stake in Harrow (NASDAQ: HROW)
Opaleye entities, including Opaleye Management Inc., Opaleye, L.P., and James Silverman, have jointly reported a beneficial ownership of 2,832,230 shares of Harrow common stock, representing 7.61% of the class. This amendment to their Schedule 13G filing indicates shared voting and dispositive power over these shares, with Opaleye, L.P. specifically holding 2,805,000 shares (7.53%). The reported percentages are based on 37,229,705 shares of Harrow outstanding as of February 25, 2026.
Harrow: Q1 Earnings Snapshot
Harrow, Inc. (HROW) reported a first-quarter loss of $27.6 million, or 74 cents per share. After adjusting for amortization costs, the loss was 63 cents per share. The pharmaceutical and drug compounding company achieved revenues of $44.2 million during the same period.
Harrow (NASDAQ: HROW) Q1 2026 revenue dips as loss widens but guidance reaffirmed
Harrow reported a Q1 2026 revenue of $44.2 million, an 8% decrease year-over-year, and a widened net loss of $27.6 million, primarily due to VEVYE gross-to-net adjustments and increased operating expenses. Despite this, the company reaffirmed its full-year 2026 revenue guidance of $350-$365 million and Adjusted EBITDA of $80-$100 million, expecting performance to be weighted towards the second half as key brands like VEVYE, IHEEZO, and TRIESENCE continue to show strong demand and market share growth. Harrow also noted the successful expansion of its sales force and upcoming product launches, including BYOOVIZ in Q3 2026, as drivers for future growth and profitability.
Harrow Announces First Quarter 2026 Financial Results
Harrow (Nasdaq: HROW) announced its first quarter 2026 financial results, highlighted by record new and total prescription performance for VEVYE® despite a decline in the overall branded dry eye category. The company reaffirmed its full-year 2026 revenue guidance of $350 million to $365 million, with second-quarter revenue expected between $71 million and $81 million, and reported cash and cash equivalents of $94.6 million as of March 31, 2026. Despite a non-recurring revenue adjustment that lowered Q1 revenue, Harrow expressed confidence in its growth trajectory and the strong demand for its key products, VEVYE, IHEEZO®, and TRIESENCE®.
Earnings Flash (HROW) Harrow, Inc. Reports Q1 Revenue $44.2M, vs. FactSet Est of $52.4M
Harrow, Inc. (HROW) reported its first-quarter revenue of $44.2 million, which fell short of FactSet's estimated $52.4 million. The company is an eyecare pharmaceutical company focused on the discovery, development, and commercialization of ophthalmic products for the US market. Harrow's stock showed a 5-day change of -0.50% and a year-to-date change of -22.37%.
Harrow Q4 Earnings Fall, Revenue Rises
Harrow reported a decline in Q4 earnings despite an increase in revenue. The company's financial performance showed a mixed picture with growth in top-line figures but a contraction in profitability for the quarter.
Harrow Health Inc stock (US4158581094): Recent share price move and earnings update
Harrow Health Inc, a specialty pharmaceutical company focused on ophthalmic therapeutics, has seen recent share price movements influenced by an updated earnings outlook and its ophthalmic drug portfolio. The company's core business revolves around developing, manufacturing, and marketing products for eye-related disorders, leveraging a diversified portfolio of branded and generic drugs. While offering exposure to a niche healthcare segment with growth potential, the stock also carries risks typical of small-cap biopharma companies.
Record 2025 Results And Boosted Investment Could Be A Game Changer For Harrow (HROW)
Harrow (HROW) reported record Q4 and FY2025 results with strong revenue growth and positive operating cash flow, despite missing EBITDA and EPS expectations due to a one-time R&D charge and increased commercial spending. Management has tempered its 2026 guidance while increasing investment in key products, signaling a strategic focus on expanding its ophthalmic portfolio over near-term profitability. The company's investment narrative hinges on its growing portfolio justifying its valuation and leading to sustained profitability, though execution risk for new product launches remains a factor.
Analysts Estimate Harrow (HROW) to Report a Decline in Earnings: What to Look Out for
Harrow (HROW) is projected to report a year-over-year decline in earnings for the quarter ended March 2026, despite an expected increase in revenues. The consensus EPS estimate has been significantly revised downward, and the company's Earnings ESP suggests a low probability of beating estimates. Investors are advised to consider other factors beyond just earnings expectations, especially given that a negative Earnings ESP does not conclusively indicate a miss.
Harrow, Inc. (NASDAQ:HROW) Receives Average Recommendation of "Moderate Buy" from Brokerages
Harrow, Inc. (NASDAQ:HROW) has received an average "Moderate Buy" rating from eleven brokerages, with an average one-year price target of $69.86, suggesting significant upside from its recent open of $40.90. The company, which specializes in ophthalmic therapeutics and diagnostics, has seen institutional investors increase their holdings, with 72.76% of its stock owned by such entities. Despite a negative P/E ratio, Harrow's financial health is marked by a strong quick ratio and significant market capitalization.
Is Harrow, Inc. (HROW) A Good Stock To Buy Now?
This article summarizes a bullish thesis on Harrow, Inc. (HROW) by M. V. Cunha, highlighting the company's strong Q4 and FY2025 revenue growth and significant operating cash flow, despite a stock decline due to conservative 2026 guidance. The thesis points to continued growth drivers like VEVYE, emerging assets like TRIESENCE, and a robust pipeline, suggesting the current valuation undervalues its potential for sustained growth and operating leverage.
Harrow (NasdaqGM:HROW) Stock Forecast & Analyst Predictions
Harrow (NasdaqGM:HROW) is projected to experience strong future growth, with earnings and revenue forecast to increase by 44.9% and 24.9% annually, respectively. Analysts have recently revised price targets, reflecting updated revenue assumptions and product guidance following Q4 results, though the overall sentiment remains largely constructive. The company anticipates becoming profitable within the next three years, outpacing the market and savings rate.
Harrow Inc (HROW) Stock Up 4.2% and Still Undervalued -- GF Scor
Harrow Inc (HROW) stock rose 4.2% to $41.41, and GuruFocus's GF Value™ assessment indicates it is currently undervalued by 9.8% with a "Modestly Undervalued" label, despite significant insider selling totaling $8.1 million. The company boasts a strong GF Score™ of 84/100, driven by excellent growth and valuation, but exhibits weaknesses in financial strength and profitability. This suggests a potential investment opportunity, though investors should exercise caution due to insider activity and financial metrics.
Harrow To Report First Quarter 2026 Financial Results After Market Close on May 11, 2026
Harrow, Inc. (Nasdaq: HROW) announced that it will report its first quarter 2026 financial results after market close on Monday, May 11, 2026. The company will host a conference call and live webcast on Tuesday, May 12, 2026, at 8:00 a.m. ET to discuss the results and provide a business update. A Letter to Stockholders will also be posted on the company's website.
Harrow posts Q1 stockholder letter May 11, then webcasts call May 12
Harrow (Nasdaq: HROW) announced it will report Q1 2026 financial results after market close on May 11, 2026, and will also post a Letter to Stockholders on its investor website. A live webcast and conference call will be held at 8:00 a.m. ET on May 12, 2026, to discuss the results and provide a business update; registration is required for telephone participants. Historical data suggests such scheduling announcements typically have limited impact on stock price, with actual reported results being the main focus.
Executive pay and board structure at Harrow (NASDAQ: HROW) 2026 meeting
Harrow, Inc. will hold its 2026 Annual Meeting on June 18, 2026, where stockholders will vote on the election of four directors, an advisory approval of executive compensation, and the ratification of Deloitte & Touche LLP as the independent auditor. The company emphasizes its "pay-for-performance" executive compensation philosophy, highlighted by performance stock units granted to its CEO and President/CFO in 2025, which are tied to ambitious stock-price hurdles. Harrow's board structure includes a Lead Independent Director and fully independent standing committees to ensure strong oversight, with three of four director nominees being independent.
Harrow announces $50M add-on senior notes offering
Harrow announced a proposed offering of $50 million in additional senior unsecured notes due 2027. These notes will be offered in a private placement to qualified institutional buyers, under Rule 144A and Regulation S of the Securities Act. The company plans to use the net proceeds from this offering for general corporate purposes.
Harrow Inc (HROW) Stock Up 3.3% and Still Undervalued -- GF Scor
Harrow Inc (HROW) increased by 3.3% to $37.10, and GuruFocus evaluates it as "Modestly Undervalued" with a GF Score™ of 86/100, suggesting strong long-term potential. Despite this undervaluation and high growth prospects, the company faces weaknesses in financial strength (4/10) and significant insider selling, with $8.1 million in shares sold over the last three months. Investors are advised to consider these risks alongside the potential for upside.
Harrow (NASDAQ:HROW) Given Buy Rating at BTIG Research
BTIG Research has reiterated a "Buy" rating for Harrow (NASDAQ:HROW) with a $63 price target, suggesting a potential upside of 54.98%. The company currently holds a "Moderate Buy" consensus rating from analysts with an average target price of $69.86. Harrow's stock trades around $40.65 with a market capitalization of $1.51 billion and significant institutional ownership.
Harrow Announces the Issuance of J-Code for IOPIDINE® 1%
Harrow announced that its IOPIDINE® 1% ophthalmic solution has been assigned a permanent J-Code (J2374) by CMS, effective July 1, 2026. This J-Code will allow for reimbursement of the drug when administered in-office, removing a significant barrier to its routine use for preventing intraocular pressure spikes after ophthalmic procedures. The company believes this will drive broader adoption of IOPIDINE 1%, enhancing patient access and improving clinical outcomes.
Does Harrow’s New LogiCare3PL Partnership (HROW) Reveal an Emerging Edge in Eyecare Distribution?
Harrow, Inc. has partnered with LogiCare3PL for U.S. distribution of its ophthalmic products, a move that could enhance efficiency and scalability for its growing eyecare portfolio. This operational shift aims to improve product access and execution for key drugs like VEVYE, IHEEZO, and TRIESENCE. Investors should, however, consider the increased debt levels from a recent US$50 million note add-on and the concentrated product risk, even as analysts remain optimistic about Harrow's revenue and earnings growth.
Eye drug used after laser procedures wins July reimbursement
Harrow (Nasdaq: HROW) announced that its IOPIDINE 1% (apraclonidine) eye drug has received a permanent J-Code (J2374) from CMS, enabling in-office reimbursement starting July 1, 2026. This designation removes a significant barrier to routine use and is expected to increase adoption for managing intraocular pressure spikes after ophthalmic laser procedures. Clinical data shows IOPIDINE 1% reduces severe post-procedure IOP spikes by approximately 91%, addressing a large market of glaucoma patients and annual laser procedures in the U.S.
Harrow Announces the Issuance of J-Code for IOPIDINE® 1%
Harrow announced that IOPIDINE® 1% ophthalmic solution has been assigned a permanent J-Code (J2374) by CMS, effective July 1, 2026. This allows for direct reimbursement to physicians for office-based administration of the drug, which is indicated to prevent intraocular pressure spikes following ophthalmic procedures. The company believes this will remove a significant barrier to routine use and increase adoption of IOPIDINE® 1%.
Does Harrow’s New LogiCare3PL Partnership (HROW) Reveal an Emerging Edge in Eyecare Distribution?
Harrow, Inc. has partnered with LogiCare3PL for U.S. distribution of its ophthalmic products, aiming to improve efficiency and nationwide availability. While this operational move could enhance Harrow's ability to scale and support its key drugs like VEVYE, IHEEZO, and TRIESENCE, the company's investment narrative also involves managing growing debt from a recent $50 million unsecured note add-on and concentrated product risk. Harrow's internal forecasts project significant revenue and earnings growth by 2028, with a fair value indicating substantial upside, though analysts are also watching execution risks and competition.
Harrow Inc (NASDAQ:HROW) Presents a Growth and Breakout Opportunity
Harrow Inc (NASDAQ:HROW) has been identified as a growth and breakout opportunity through a combined fundamental and technical analysis approach. The pharmaceutical company exhibits strong historical and projected growth metrics, with analysts expecting significant increases in EPS and revenue. Technically, HROW shows a consolidation pattern near resistance, suggesting a potential breakout aligned with its strong fundamental story.
LogiCare3PL Selected as Distribution Partner by Harrow
LogiCare3PL has been chosen by Harrow, Inc. as its distribution partner for Harrow's ophthalmic disease management solutions across the U.S. market. The partnership, effective February 1, 2026, involves LogiCare3PL providing non-title and 3PL title distribution services, emphasizing rapid onboarding and efficient market access for Harrow's products. Both companies highlight the collaboration's focus on flexibility, customer-centricity, and quick execution.
LogiCare3PL Selected as Distribution Partner by Harrow
LogiCare3PL has been chosen by Harrow, Inc. as its distribution partner for Harrow's ophthalmic disease management solutions. Since February 1, 2026, LogiCare3PL has been providing both non-title and 3PL title distribution services to support Harrow's product distribution across the U.S. market. This partnership aims to enhance the availability of Harrow's products nationwide.
Harrow shifts U.S. eye drug distribution to LogiCare3PL in 4 weeks
Harrow Inc. has selected LogiCare3PL as its U.S. distribution partner for ophthalmic disease management solutions, with the agreement effective February 1, 2026. LogiCare3PL successfully onboarded Harrow's products within four weeks, providing both non-title and 3PL title distribution services nationwide. This partnership aims to provide faster, more cost-effective market access and ensures continuity of supply for Harrow's ophthalmic portfolio.
